Pediatric Osteosarcoma Therapeutics Market Exhibits a Revenue CAGR of 4.1% Durin… – Press Release


Newark, New Castle, USA, April 25, 2023 (GLOBE NEWSWIRE) — As per the report by Growth Plus Reports, the global pediatric osteosarcoma therapeutics market is expected to register a revenue CAGR of 4.1% by 2031.

The global pediatric osteosarcoma therapeutics market was valued and expected to rise with a significant revenue share during the forecast period. Pediatric osteosarcoma is a type of bone cancer primarily affecting children and adolescents. The therapy combines chemotherapy, including antineoplastic agents, antiemetic agents, colony-stimulating factors, and antidotes. 

Recent Development in Pediatric Osteosarcoma Therapeutics Market: 

  • In September 2022, Dovitinib, an experimental therapy for osteosarcoma, was given the FDA’s rare pediatric disease designation (RPDD) by Oncoheroes Biosciences, Inc. 
  • In February 2022, The FDA granted QSAM Biosciences Inc. the rare pediatric disease designation (RPDD) for CycloSam, a drug used to treat osteosarcoma. This nuclear technology employs DOTMP, a chelator thought to eliminate off-target migration and targets sites of high bone turnover, making it an ideal agent to treat primary and secondary bone cancers. 

Download PDF Brochure of Pediatric Osteosarcoma Therapeutics Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at:

                            Pediatric Osteosarcoma Therapeutics Market Scope

Report Attribute Details
Growth Rate CAGR of 4.1% from 2023 to 2031
Base Year for Estimation 2022
Forecast Period 2023-2031
Historical Year 2022
Segments Covered Therapy Type, Drug Class, End-user, and Region.
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Key Takeaways: 

  • The large prevalence of pediatric osteosarcoma is driving the market revenue expansion. 
  • The rising demand for personalized therapeutics is boosting market revenue growth.